Genmab A (GMAB) Operating Expenses (2018 - 2026)
Genmab A (GMAB) reported Operating Expenses of -$716.0 million for Q1 2026, down 35.86% on a YoY basis from -$1.1 billion in Q1 2025, and down 27.18% quarter-over-quarter from -$563.0 million in Q3 2025.
Genmab A (GMAB) Operating Expenses (2018 - 2026) Analysis & Trends
Genmab A has reported Operating Expenses for 6 years, with the latest figure at -$716.0 million in Q1 2026.
- For the quarter ending Q1 2026, Operating Expenses fell 35.86% year-over-year to -$716.0 million; the trailing twelve-month figure through Mar 2026 stood at -$1.8 billion (down 17.01% YoY), and the FY2025 full-year result was $2.7 billion, up 23.55% from the prior year.
- Operating Expenses for Q1 2026 stood at -$716.0 million, down from -$563.0 million in the prior quarter.
- The five-year high for Operating Expenses was -$487.0 million in Q1 2024, with the low at -$716.0 million in Q1 2026.
- Historically, Operating Expenses has averaged -$558.1 million across 3 years, with a median of -$543.0 million in 2024.
- Annual changes were most pronounced in 2025 — Operating Expenses fell 4.05% — and 2026, when it plunged 35.86%.
- Genmab A's Operating Expenses stood at -$506.0 million in 2024, then retreated by 11.26% to -$563.0 million in 2025, then declined by 27.18% to -$716.0 million in 2026.
- The last three Operating Expenses figures came in at -$716.0 million (Q1 2026), -$563.0 million (Q3 2025), and -$565.0 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 4.33 Mn |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | 32.68 Mn |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 2.97 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | -138.30 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 15.76 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | -3.82 Mn |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | 574,669.00 |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 1.85 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -67.40 Mn |
| 10 | Genmab A | 48.34 Bn | 46.82 Bn | 831.00 Mn | -716.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -716.00 Mn |
| Sep 30, 2025 | -563.00 Mn |
| Jun 30, 2025 | -565.00 Mn |
| Mar 31, 2025 | -527.00 Mn |
| Sep 30, 2024 | -506.00 Mn |
| Jun 30, 2024 | -543.00 Mn |
| Mar 31, 2024 | -487.00 Mn |
| Sep 30, 2020 | -866.00 |
| Dec 31, 2019 | -689.00 |
| Sep 30, 2019 | -689.11 Mn |
| Dec 31, 2018 | -398.42 Mn |